Twelve hours a day, on borrowed time: a Chinese tech founder's race against his own diagnosis

A terminally ill Chinese internet entrepreneur is working twelve-hour days at a biotech firm he founded to develop a treatment for the same disease that is killing him, the South China Morning Post reported on 21 June 2026. The founder, who told the paper "only death can stop me," is pouring what remains of his energy into a once-obscure corner of Chinese biotech, betting that a domestic pipeline of therapies can move faster than his own decline.

The story lands at an awkward moment for Chinese biomedical ambition. Beijing has spent the best part of a decade trying to push the country up the value chain from generics-manufacturer to originator of cutting-edge therapies, and rare neurological diseases have become a quiet proving ground. A patient-founder forcing the pace — publicly, on camera, against a known terminal horizon — compresses several of those pressures into a single human narrative.

The diagnosis, and the company built around it

According to SCMP's profile, the founder received a diagnosis of amyotrophic lateral sclerosis, the degenerative motor-neuron condition more commonly known as ALS or, in some markets, motor neuron disease. The disease progressively destroys the nerve cells that control voluntary movement; median survival from symptom onset is typically measured in years rather than decades, and there is no cure. Rather than wind down his affairs, he incorporated a new venture and, the paper reports, now logs roughly twelve hours a day in the laboratory or in management meetings, with the explicit goal of pushing a candidate therapy through preclinical and clinical work.

SCMP frames the project as part of a wider turn inside Chinese biotech: founders with personal stakes in under-served diseases — particularly neurodegenerative and rare conditions that Western pipelines have historically deprioritised — building small, mission-driven teams rather than chasing the oncology and metabolic-disease markets that dominate global venture flows.

What is genuinely different about the Chinese context

The Western news cycle on Chinese biotech tends to fixate on two things: national-security anxieties around genomic data, and the price competition that Chinese drugmakers bring to global markets. The patient-founder story sits in a third lane that gets far less coverage — small, founder-driven labs working on indications the multinational pharma model has historically underfunded.

Two structural features make that lane more navigable inside China than it would be in Boston or Basel. First, the regulatory pathway for novel therapies has been progressively compressed: what used to be a multi-year, multi-jurisdiction approval slog can now, for certain categories of drug, be threaded through streamlined domestic review. Second, hospital networks tied to major research universities provide early clinical-trial access at a scale that few single-country ecosystems can match. SCMP's reporting does not romanticise either feature — it notes that the founder is operating against a regulatory clock as much as a biological one — but it makes clear why a patient-led model is even conceivable.

There is also a quieter cultural register the story exposes. Chinese-language coverage of terminal illness in public figures tends to lean into a stoic, work-ethic frame; SCMP's profile sits comfortably inside that tradition without quite naming it. A reader who only knew Chinese biotech from Western wire coverage would miss this entirely.

What remains contested

Several claims in the SCMP piece are not independently corroborated in publicly available English-language sources at the time of writing. The paper does not name the specific candidate therapy the company is developing, nor does it disclose the size of any financing round or the institutional backers. The twelve-hour figure comes from the founder's own description of his schedule and is not a third-party measurement. The clinical timeline implied — preclinical work, Phase I, Phase II — is laid out in general terms rather than tied to a specific trial registration.

That matters because ALS pipelines are littered with credible-sounding preclinical stories that have not survived contact with human trials. The most-cited counterpoint is the long-running case of BrainStorm Cell Therapeutics' NurOwn, a stem-cell therapy that showed promising Phase II data before failing its Phase III readout in 2020; the field has since grown warier of small-cohort, mechanism-promising early results. Any reader tempted to treat the SCMP profile as a forecast should hold it instead as a dispatch from a founder at work.

Stakes: a single patient, and a model under stress

If the company advances a candidate into human trials, the immediate beneficiary is obvious: the founder himself, whose own disease will determine whether the timeline is fast enough. The wider stakes are more interesting. A Chinese-origin ALS therapy that moved through domestic review would put pressure on a global pipeline that has produced only a handful of approved disease-modifying treatments — most prominently edaravone, marketed as Radicuta by Mitsubishi Tanabe, and the more recent AMX0035 (Relyvrio / Albrioza), whose own commercial and clinical trajectory has been turbulent.

It would also test a hypothesis Beijing has been writing into its five-year plans: that founder-led, mission-driven biotech can deliver therapies the multinational model has under-prioritised. The SCMP story is not, on its own, evidence for or against that hypothesis. It is, at most, an early data point from one founder who has decided that the only way to find out is to outwork his own diagnosis.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://en.wikipedia.org/wiki/Amyotrophic_lateral_sclerosis
• https://en.wikipedia.org/wiki/NurOwn
• https://en.wikipedia.org/wiki/Edaravone